FDA Brief

Warning letters Drugs

FDA warning letter to

World Perfumes Inc.

High riskIssued Oct 29, 2025Posted Nov 18, 2025Center for Drug Evaluation and Research (CDER)

World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

What happened

FDA inspected World Perfumes' drug manufacturing facility in Opa-Locka, FL, from May 5 to 9, 2025. FDA found that the company did not test incoming ingredients to confirm identity, including ethanol for methanol and glycerin for diethylene glycol or ethylene glycol, and that its water system had dead legs and was not adequately monitored for microbes. FDA reviewed the company's May 29, 2025 response and found it inadequate.

What FDA found

  1. Did not run at least one test to confirm the identity of each incoming ingredient lot, such as ethanol and glycerin, before use.

    21 CFR 211.84(d)(1)
  2. Did not test incoming ethanol for methanol or show it met official impurity limits, and used nonpharmaceutical-grade ethanol.

    21 CFR 211.84(d)(1)
  3. Did not test glycerin and other high-risk ingredients for diethylene glycol or ethylene glycol before use.

    21 CFR 211.84(d)(1)
  4. Used a water system with dead legs and piping that could not be adequately sanitized.

    21 CFR 211.63 and 21 CFR 211.100(a)
  5. Did not adequately monitor or test its water for objectionable microorganisms such as Burkholderia cepacia complex or sample manufacturing points of use.

    21 CFR 211.63 and 21 CFR 211.100(a)
  6. Did not validate its alternative microbiological test method used for water and drug product samples.

What FDA wants

FDA tells the company to respond in writing within 15 working days with corrections and preventive actions, and to provide methanol and DEG/EG test results within 30 calendar days, plus risk assessments and a water-system remediation plan.

Who should pay attention

  • brands that buy OTC oral or topical drugs from this contract manufacturer
  • companies relying on ethanol or glycerin ingredient certificates
  • quality teams at drug manufacturers with similar water systems

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. TCI Co., Ltd BioCosme PABP BRANCH

    FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.

    High risk
  3. Babikian Healthcare Products CJSC

    FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium